Page 20 - Haematologica Vol. 110 - January 2025

EDITORIAL
J. Desroches and D. Villa
icities. However, given that most combination therapies included a continuous BTKi with a fixed number of cycles of the other agent(s), it is likely that the previously reported AE were truly related to the BTKi.
Overall, the findings from the analysis by Shah and col- leagues support the use of pirtobrutinib in patients with low-grade B-cell lymphomas who have previously discon- tinued a different BTKi due to intolerance but without PD. The drug’s improved tolerability profile, coupled with its sustained efficacy, reinforces its position as a fearsome player in the B-cell lymphoma arena. This ‘brute’ with a softer side is an excellent option for patients who experi- enced toxicities on a covalent BTKi, although 25-30% pa-
References
1. Shah NN, Wang M, Roeker LE, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2024:109(1):92-102.
2. Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single- agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799-1807.
3. Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132(Suppl 1):1871.
4. Brandhuber B, Gomez E, Smith S, et al. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Clin Lymphoma Myeloma Leuk. 2018;18:S216.
5. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33-44.
6. Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent
tients will discontinue pirtobrutinib due to PD, highlighting the need for novel therapies.
Disclosures
DV reports honoraria and Advisory Boards from Janssen, BeiGene, AstraZeneca, Incyte, BMS/Celgene, Kite/Gilead, Eli Lilly, Roche, and Abbvie, and research funding (to the institution) from Roche and AstraZeneca. JD has no conflicts of interest to disclose.
Contributions
JD and DV wrote the manuscript.
Bruton tyrosine kinase inhibitor pretreated mantle-cell
lymphoma. J Clin Oncol. 2023;41(24):3988-3997.
7. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of
the first randomized phase III trial. J Clin Oncol.
2021;39(31):3441-3452.
8. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or
ibrutinib in relapsed or refractory chronic lymphocytic
leukemia. N Engl J Med. 2023;388(4):319-332.
9. Rogers KA, Thompson PA, Allan JN, et al. Phase II study of
acalabrutinib in ibrutinib-intolerant patients with relapsed/ refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364-2373.
10. Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10(1):e35-e45.
Haematologica | 110 January 2025
12